The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates...

Area of Science:

• Immunology
• Pharmacology
• Gastroenterology

Background:

• Lymphocyte trafficking is crucial for immune responses and is regulated by sphingosine 1-phosphate (S1P) and its receptor S1P₁.
• Immune-mediated inflammatory disorders, such as ulcerative colitis, involve dysregulated immune cell activity.

Purpose of the Study:

• To evaluate the preclinical pharmacology of etrasimod, a novel oral S1P receptor modulator.
• To assess etrasimod's efficacy in a mouse model of colitis.

Main Methods:

• Etrasimod's binding and functional activity at various S1P receptors (S1P₁, S1P₂, S1P₃, S1P₄, S1P₅) were assessed.
• A dose-dependent relationship between etrasimod concentration and lymphocyte count was examined in mice.
• Efficacy was evaluated in a CD4⁺CD45RB^high T-cell transfer mouse model of colitis.

Main Results:

• Etrasimod demonstrated full agonist activity at S1P₁ receptors across species and partial agonist activity at S1P₄ and S1P₅ receptors.
• No agonist or antagonist activity was observed at S1P₂ or S1P₃ receptors.
• A dose-dependent decrease in lymphocyte count was observed, and chronic etrasimod treatment attenuated colitis in the mouse model.

Conclusions:

• Etrasimod exhibits a promising preclinical pharmacological profile as an S1P receptor modulator.
• These findings support the clinical development of etrasimod for immune-mediated inflammatory disorders like ulcerative colitis.